Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards.

Nauck, Michael A; Meier, Juris J

Nauck, Michael A; Meier, Juris J.

Nauck MA; Diabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany michael.nauck@rub.de.
Meier JJ; Diabetes Division, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany.

Diabetes Care ; 43(12): 2906-2909, 2020 12.

Article in English | MEDLINE | ID: covidwho-840098

Subject(s)

Coronavirus Infections; Diabetes Mellitus, Type 2; Pandemics; Pneumonia, Viral; Betacoronavirus; COVID-19; Hospitalization; Humans; Retrospective Studies; SARS-CoV-2; Sitagliptin Phosphate/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Diabetes Mellitus, Type 2 / Pandemics Type of study: Observational study Limits: Humans Language: English Journal: Diabetes Care Year: 2020 Document Type: Article Affiliation country: Dci20-0062

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google